Liver cancer is the second leading cause of cancer mortality and hepatocellular carcinoma (HCC) is the 16th absolute cause of death world-ide. 1 In the United States, liver cancer mortality shows an increasing trend in contrast to what is observed for most cancer types. 2 Hepatocellular carcinoma accounts for 80% of all primary liver cancers worldwide.
Besides the high prevalence of hepatitis C virus (HCV) infection as the main responsible for increasing HCC rates in Western countries, 3 other etiologies have been identified increasing incidence of HCC (hepatitis B virus [HBV] infection, alcohol abuse, obesity, and metabolic syndrome). All these risk factors lead to chronic inflammation, hepatic fibrosis, and eventually cirrhosis. Although surveillance programs for patients at risk of developing HCC have improved significantly in Keywords ► hepatocellular carcinoma ► molecular profiling ► targeted therapies ► cirrhosis ► gene signatures Abstract Hepatocellular carcinoma (HCC) is a complex disease with a dismal prognosis. Consequently, a translational approach is required to personalized clinical decision making to improve survival of HCC patients. Molecular signatures from cirrhotic livers and single nucleotide polymorphism have been linked with HCC occurrence. Identification of highrisk populations will be useful to design chemopreventive trials. In addition, molecular signatures derived from tumor and nontumor samples are associated with early tumor recurrence due to metastasis and late tumor recurrence due to de novo carcinogenesis after curative treatment, respectively. Identification of patients with a high risk of relapse will guide adjuvant randomized trials. The genetic landscape drawn by nextgeneration sequencing has highlighted the genomic diversity of HCC. Genetic drivers recurrently mutated belong to different signaling pathways including telomere maintenance, cell-cycle regulators, chromatin remodeling, Wnt/b-catenin, RAS/RAF/MAPK kinase, and AKT/mTOR pathway. These cancer genes will be ideally targeted by biotherapies as a paradigm of stratified medicine adapted to tumor biology.
the past years, 4 only one-third of HCC patients are diagnosed at early stages, when they are still eligible for potentially curative therapies such as resection, transplantation, or local ablation. 5 Patients with intermediate stages benefit from chemoembolization, whereas those at advanced stages would still have short survival expectancy despite the improved outcome obtained with sorafenib as the first systemic therapy. 6 Advances in genomics, in parallel with the constitution of large patient cohorts encompassing exhaustive databases and referenced biobanks in clinical research units, have greatly facilitated better understanding of the molecular biology of this pathology. As is already the case for other types of cancers, molecular profiling may help to identify patients that will benefit from selective therapeutic targeting. Although molecular profiling is expected to be a valuable tool in clinical practice of HCC, it has not yet been integrated in the therapeutic decision-making algorithm and in the clinical management of HCC.
In this review, we describe the relevance of genomics as a novel prediction, diagnostic, and prognostic tool in HCC, and discuss how integration of this molecular data into the existing clinical algorithms might add valuable information to daily clinical practice leading to a more efficient treatment approach in HCC.
Contribution of Molecular Profiling for Risk Assessment of HCC
In Western countries, HCC arises on a cirrhotic background in up to 90% of cases.
7 Hepatocellular carcinoma occurs in onethird of cirrhotic patients during their lifespan and is the main cause of death among them. 5 Irrespective of the etiology, established cirrhosis serves as the factor that fosters initiation and promotion of carcinogenesis by facilitating genetic aberrations and cellular transformation, which is often referred to as "field effect." 8 Even after complete surgical resection or local ablation of early HCC tumors, nearly 70 to 80% of patients develop subsequent recurrence due to tumor dissemination or de novo tumors 5 caused by the cancer-prone microenvironment in the surrounding cirrhotic liver. For HBV and HCV etiological agents, hepatocarcinogenesis is tightly associated with an inflammation scenario accompanied by immune-mediated destruction of infected hepatocytes followed by regeneration, oxidative stress, and DNA damage, which presumably leads to accumulating potentially oncogenic mutations. 7 Furthermore, viral products such as HCV core protein may have direct carcinogenic effects by inducing activation of signaling pathways such as MAPK and activator protein-(AP-) 1. 9 In fact, severity of the underlying cirrhosis is correlated with increasing risk of HCC, 10 especially in HCVinfected patients.
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Hepatocellular carcinoma is an attractive target of preventive intervention because at-risk individuals can readily be identified due to the presence of underlying viral hepatitis or other liver diseases. Ultrasound-based liver imaging is the most widely used and cost-effective screening strategy used for high-risk populations. Nonetheless, even with ultrasoundbased screening programs, the development of HCC is 2 to 3% annual rate in at-risk populations. Therefore, the identification of molecular biomarkers for defining populations at a very high risk of cancer development would be extremely useful for chemopreventive intervention.
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Contribution of Transcriptomic Signatures in Prediction of HCC Development
Many studies have established gene signatures based on array-gene expression profiling from cirrhotic and adjacent tissue of HCC. [13] [14] [15] These signatures have been demonstrated to serve as a sensitive "readout" of the biologic state of the liver, reflecting molecular aberrations that may govern risk of HCC development and dissemination. 
SNPs Predisposing to HCC
Genetic host factors play an important role in HCC development. The most common form of genetic variation between individuals are single nucleotide polymorphisms (SNPs), which are a variation at a particular nucleotide locus from the DNA. Although the vast majority of these modifications are situated in noncoding regions, some can alter either protein function or expression, affecting biological pathways. Single nucleotide polymorphisms, located in genes involved in carcinogenesis, may contribute to an individual's susceptibility to cancer, partially explaining the genetic heritability of this disease. Many studies have described associations between various SNPs and the presence of HCC, through two different approaches. "Candidate-gene" approaches are normally based on the hypothesis that a known identified variant located in a gene implicated in hepatocarcinogenesis might be associated with a higher risk of HCC occurrence. Nonhypothesis driven approaches use a genome-wide association study (GWAS) to compare genotypic distributions of thousands of SNPs in HCC patients and controls to reveal unsuspected variants associated with HCC.
Main pathways containing variants associated with HCC are oxidative stress and detoxifying systems, iron metabolism, inflammatory and immune responses, DNA repair mechanisms, and systems involved in cell-cycle regulation.
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One interesting example of a genetic variant detected through the candidate-gene approach is a SNP located in the epidermal growth factor (EGF) gene (rs4444903) and associated with increased EGF expression (by expanding the half-life of EGF protein) and elevated risk of HCC development in cirrhotic Caucasian patients. 22, 23 On the other hand, through GWAS several genetic regions were found to have statistically significant association with HCC in chronic hepatitis C patients. These are the 5′ Although there are a huge number of publications in this field, most studies suffer from major methodological drawbacks such as poor selection of control samples (patients with other liver diseases), retrospective and single-center design, underpowered sample size, or lack of validation in distinct ethnic populations. As a consequence, external validation in well-characterized populations of different ancestry is needed before effectively translating these results to clinical practice.
Contribution of Molecular Profiling for Diagnosis
Noninvasive diagnosis using the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases (EASL/AASLD) criteria is usually applicable in HCC tumors of more than 2 cm, developed in patients with cirrhosis; most of the time these tumors do not require percutaneous biopsies. 29, 30 However, there are frequent diagnostic difficulties in tumors smaller than 2 cm, particularly to discriminate between high-grade dysplastic nodules (HGDN) and early HCC in cirrhotic patients. As imaging is only accurate for defining the diagnosis of small nodules in half of cases, a liver biopsy is often indicated, though the pathological diagnosis can remain difficult even for expert pathologists. 29, [31] [32] [33] Moreover, in carcinogenesis developed in normal liver, differential diagnosis between very well differentiated HCC and HCA is challenging. Even if this situation is a rare event, it is important to diagnose benign or malignant tumors with a high degree of confidence; overall, the major diagnostic issue in primary liver tumors is related to the critical steps of malignant transformation from hepatic adenoma or HGDN into HCC. 34 Consequently, we need to identify new biomarkers with two major goals:
Identification of preneoplastic lesions at high risk of malignant transformation 2. Discrimination of HCC from preneoplastic lesions
Contribution of Immunohistochemistry in Pathological Diagnosis
In patients with cirrhosis, HCC occurs from a multistep process of carcinogenesis following the sequence: dysplastic nodules > very early HCC > small and progressed HCC.
33,35
However, interobserver agreement for the diagnosis of very early HCC and HGDN is limited (kappa value from 0.30-0.49) despite international consensus and the introduction of stromal invasion as histological criteria for malignancy. Identification of minute HCC is still a major issue because the treatment of precancerous liver lesions is not currently codified by guidelines. In contrast, detection of HCC at initial stages is clearly a major goal to propose curative treatment including liver resection, local ablation, or liver transplantation. 29, 31 A combination of three immunohistochemical markers including glypican 3, HSP70, and glutamine synthase help to discriminate early HCC from HGDN with a sensitivity from 46% to 72% and a specificity of 100%. 36 These three markers have been validated by an external group, although it was pointed out that they only slightly increase the diagnostic accuracy in an expert setting. 37 This combination of markers has been endorsed for diagnosis by the EASL guidelines.
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Additional immunohistochemical markers have been proposed for early diagnosis, but they require further validation.
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Transcriptomic Signatures
Molecular signatures derived from microarray experiments analyzing whole genome expression have been proposed to discriminate early HCC from HGDN. Two studies 13, 15 identified genes differentially expressed by microarray and established genes signatures (including 134 and 120 genes, respectively) for each step of the gradual process of carcinogenesis from cirrhotic tissue to HCC, in respectively HCV-and HBV-related cirrhosis. A more restricted approach combining 13 genes (TERT, IGF2, GJB2, TEK, TIAM1, CXCL12, TOP2A, A2M, PLG, CDKN2A, PDGFRA, MKI67 and THBS1) was proposed to distinguish dysplastic cirrhotic nodules and early cancer in cirrhosis. 39 Finally, we identified a combination of three genes including glypican 3, LYVE1, and survivin assessed by quantitative RT-PCR as a diagnostic tool for very early HCC.
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This three-gene set has a sensitivity of 95% and a specificity of 94% for discriminating HGDN and early tumors less than 2 cm. A unified comparison of the accuracy of these signatures with the three immunohistochemical markers (GPC3, HSP70, and GS) is required.
Gene Mutations Profile
Recently, somatic mutations in the promoter of TERT that increase the expression of telomerase were identified in 59% of HCCs. 41, 42 Strikingly, 25% of cirrhotic preneoplastic lesions also harbored somatic TERT promoter mutations. This TERT promoter mutation is the first recurrent somatic genetic alteration identified in cirrhotic preneoplastic lesions.
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These results suggest that cirrhotic preneoplastic lesions harboring TERT promoter mutations might have a higher risk of malignant transformation in HCC. It also provides the rationale to test drugs targeting telomerase in chemoprevention or in a curative attempt in the field of hepatocarcinogenesis (►Fig. 1). 
Cirrhosis
Malignant Transformation of Hepatocellular Adenoma
Hepatocellular adenoma (HCA) is a bona fide example of a translation of genomic studies in clinical practice. 34 Hepatocellular adenomas are rare benign hepatocellular tumors occurring in normal liver and mainly in young women taking oral contraception. 34 Malignant transformation of HCA in HCC is a rare event with a frequency estimated around 5%. Hepatocellular adenomas harboring CTNNB1 mutations activating β-catenin have a high risk of malignant transformation in HCC and consequently should be treated by liver resection.
44,45
More recently, we also identified somatic TERT promoter mutations as a late genetic event in the mutational process of malignant transformation of HCA. 41, 46 We showed that borderline lesions between HCA and HCC harbored TERT promoter mutations in 17% of the cases and HCA with overt transformation in HCC in 56% of the cases. 41, 46 In contrast, classical adenomas did not harbor TERT promoter mutations. Then, according to the aims of biomarker identification, CTNNB1 mutations in HCA are able to identify lesions at high risk of malignant transformation and TERT promoter mutation is a potential biomarker of malignant transformation of HCA in HCC discriminating HCC from preneoplastic lesions.
Molecular Prognosis Markers and Consequences for Therapeutic Decision
The assessment of prognosis is a difficult and fine art in the field of HCC. 47 Numerous factors converge to influence the risk of tumor recurrence and the risk of death. In contrast to most other solid tumors, the risk of demise in patients with HCC developed on a cirrhotic background is related to primary tumor recurrence, de novo carcinogenesis and death derived from liver failure. 47 In addition, after curative treatment such liver resection and local ablation, the timeframe of tumor recurrence is roughly related to these factors. Early tumor recurrence, occurring in the 2 years following surgery, is usually related to intrahepatic metastasis of the initial tumor and consequently related to tumor biology. 48, 49 In contrast, late tumor recurrence, occurring after 2 years following a curative treatment, is more frequently due to de novo carcinogenesis in patients with cirrhosis and is related to microenvironment features. Intuitively, prognosis of patients with very early stage HCC (BCLC 0) 29 after successful removal is mostly related to de novo carcinogenesis and occurrence of liver dysfunction whereas prognosis of HCC at advanced stages (BCLC C) 29 is mostly related to tumor biology. However, prognosis of patients with HCC developed on a cirrhotic background and treated by resection depends on both tumor and cirrhotic biology. 49, 50 There is a continuum between very early stages and advanced stages and the magnitude of each effect (tumor biology vs. de novo carcinogenesis) in each stage have to be refined. 47 Consequently, several molecular signatures related to one of these events have been identified during the last decade.
Design of Prognostic Biomarker Studies
Prognostic biomarkers need to fulfill several criteria to assure their robustness before being implemented in a clinical routine. 29, 51 The recurrent failure of biomarker translation in clinical practice is mainly due to the inadequate design of prognostic studies. The REMARK (reporting recommendations for tumor marker prognostic studies) and PROGRESS (prognosis research strategy) reports have paved the way for the identification and validation of prognostic biomarkers in translational research. [52] [53] [54] [55] [56] The EASL guidelines 29 adopted strict criteria for assessing biomarkers in the HCC research field, summarized as follows:
•
18 When all these items are validated, the new biomarker could be suitable to be tested in clinical trial before implementation in routine practice.
Molecular Prognosis Marker Related to Cirrhotic Biology
Biological signals from cirrhotic tissue have emerged as a predictor of de novo carcinogenesis and late recurrence after HCC resection. As described in the section "Contribution of Transcriptomic Signatures in Prediction of HCC Development," two molecular signatures derived from cirrhotic samples have been associated with overall survival and late recurrence in HCC patients treated by resection. 8, 16 Moreover, combining the molecular signatures derived from tumors and from cirrhotic tissues could refine prognosis prediction: Associating the five-gene score from the tumor and the poor survival signature from the cirrhotic tissue predicts prognosis more accurately than either signature alone.
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Molecular Prognosis Marker Related to Tumor Biology
A huge effort has been performed by several teams to identify prognostic molecular signatures of HCC using transcriptomic assays. Now, more than 20 signatures derived from tumor tissues have been published. A seminal study has identified two subgroups of HCC named A and B with different prognosis. 57 The HCC subgroup A associated with poor prognosis was characterized by dysregulation in proliferative genes (the socalled proliferative subgroup). Then, six subgroups of HCC (G1-G6) were described closely related to clinical and genetic features. 58 with a poor survival in HCC patients related to HBV infection and with high level of IL6 and NFKB. 74 Interestingly, a low level of mir26 was suggested to predict a better response to adjuvant therapy with interferon alpha (IFN-α) . 74 However, validation of the prognostic and predictive value of mir26 is warranted in Western countries where IFN-α is not routinely used in the adjuvant setting.
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Integration of Molecular Signature with Staging System and Pathological Features: Potential Consequences in Clinical Practice
In the future, integration of molecular signature from tumor and/or cirrhosis with staging system and pathological features will be useful to refine the patient's staging and stratification. As a proof of principle to overcome the traditional dichotomy between molecular features and clinical/ pathological features, we proposed a composite nomogram that integrates the five-gene score, the BCLC staging, and the microvascular invasion to predict individually the risk of death. 50 ►Fig. 1 summarizes the potential usefulness of molecular information in chemoprevention early treatment and trial stratification. In this line, the main utility of the molecular signature in clinical practice will be patient stratification according to their risk of relapse and death. Identification of patients with a high risk of de novo carcinogenesis through profiling of the cirrhotic tissues will help to identify a subgroup of patient candidates to a chemopreventive trial.
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In the field of liver transplantation for HCC, identification of HCC outside Milan criteria with a low risk of recurrence will help to refine and extend the criteria for liver transplantation. 47 In addition, the recent negative results of the adjuvant randomized trial comparing sorafenib against placebo after curative treatment of HCC have underlined the need to identify patients at even higher risk of relapse that will benefit from adjuvant therapies. 76 This strategy is currently used in adjuvant clinical trials for other cancers like breast cancer. 77 To ensure their full use in clinical practice, the different molecular signatures have to be validated in other curative treatments (i.e., local) and in advanced HCC, but also in biopsies where the small amount of materials could be challenging.
Molecular Profiling to Define New Therapeutic Targets and Oncogenic Pathways
Recent successes in the treatment of cancer using molecular targeted therapies derived from the identification of genomic alterations have improved patient survival. Examples of these treatments include imatinib in leukemia patients with the gene fusion BCR-ABL, gefitinib or erlotinib for nonsmall cell lung cancer with mutations of the EGF receptor, or trastuzumab for breast cancer patients showing amplified HER2/neu receptor.
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However, for HCC, so far only the multikinase inhibitor sorafenib has been shown to improve survival of advanced HCC patients. 6 Because the median life expectancy of sorafenib-treated patients is one year and recently finished phase 3 clinical trials testing new biotherapies in nonselected patients have failed to improve patient survival, 76 there is an urgent need for additional efficient therapies for advanced HCC. Taking into consideration patients' genomic features in the design of clinical studies has been suggested to improve the trials' rates of success.
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We provide here a comprehensive revision of some genomic features that have been proposed to drive HCC carcinogenesis, and thus provide preclinical proof of concept for selective molecular targeting in early clinical trials.
Among all tumor-driver genes, of special interest are those responsible for oncogenic addition. Tumors developed under oncogenic addition are largely dependent on a single activated oncogene, and when submitted to a treatment targeting this single gene these tumors have higher rates of curative response. In HCC, such targeted therapies are still a challenge. As described in the introduction, HCC may occur on very different liver backgrounds (HBV, HCV, metabolic syndrome in abnormal noncirrhotic livers or cirrhotic livers); this is reflected in the complexity of this malignancy at the molecular level. [3] [4] [5] 32 Each of these HCC scenarios is characterized by different genetic and epigenetic alterations, thus hindering the identification of relevant oncogenic addictions. This is aggravated by additional levels of complexity. Development of solid tumors such as HCC is estimated to require (1) at least three signaling networks being simultaneously altered, 81 or (2) five to eight alterations in driver genes. However, they present dozens of passenger genetic alterations (somatic mutations, chromosomal translocations, amplifications, or deletions) that do not provide significant growth advantage. 82 In contrast, hematological tumors typically present one single pathway altered, and exhibit far fewer somatic mutations. 81, 82 It is, therefore, not surprising that discovering the right HCC therapy turned out to be a complex task. Understanding the mechanisms behind the pathogenesis, at the molecular level, have vastly contributed to the development of novel therapies. In this line of work, new-generation sequencing studies have contributed enormously. Genomic studies in multiple HCCs have confirmed previously identified mutated genes (TP53, CTNNB1 and AXIN1) and have also unraveled several novel HCC driver genes among which are TERT, ARID1A, ARID2, RPS6KA3, PIK3CA, IRF2, NFE2L2, and KEAP (►Table 2). 41, 83, 84 Functional classification of these mutated genes suggested that the key signaling pathways for HCC are associated to Wnt/b-catenin signaling, chromatin remodeling, oxidative stress, and receptor signaling (EGF, PDGF, FGF, VEGF, and IGF) as well as to Ras-Raf-MAPK and PI3K/Akt signaling (►Table 2).
Targeting the Most Prevalent HCC Alterations
Therapeutic interventions based on TERT, CTNNB1 (b-catenin), or TP53-the most prevalent molecular alterations described to date in HCC (60%, 85 The lack of approved targeted therapies specific for TERT, Wnt/b-catenin pathway or TP53, provides additional opportunities to identify HCC patients who may profit from alternative targeted therapies. However, additional efforts are warranted to decipher these signaling pathways and to identify new compounds that could target these driver genes with limited collateral toxic effects.
Targeting Raf
Mutations and other genetic alterations activating the RasRaf-MAPK pathway were soon of particular interest in HCC for therapeutic reasons. Despite the fact that mutations of the RAF/MAPK axis are uncommon in HCC (< 5%), 79 universal activation of RAf/MAPK signaling has been described in advanced HCC. 86 Activation of this critical pathway results from upstream signaling by EGF, IGF, and MET activation, and from the epigenetic silencing of tumor suppressors such as NORE1A and RASSF1A. 87 An exploratory pilot clinical trial is currently ongoing targeting patients with RAS mutations by the MEK inhibitor refametinib (NCT01915602; http://clinicaltrials.gov/).
Targeting IGF Signaling
One fourth of the HCC patients present an allelic loss affecting one of the IGF2 receptors (IGF2R). 88 In addition, 10% of the HCC patients show enhanced IGF2 expression, and the IGF binding proteins IGFBP2 and IGFBP3 have been shown to be deregulated as well. 88 Furthermore, the IGF1R was shown to be activated in 21% of HCCs. 88 Thus, promising HCC-therapeutic strategies either targeting the IGF ligands or blocking the IGF receptors are currently being assessed (►Table 2).
Targeting mTOR
Another key pathway in HCC is mTOR. About 40 to 50% of the HCCs present disrupted mTOR signaling 60 and would be candidates for treatments based on mTOR inhibition such as everolimus (►Table 2). Everolimus failed to improve survival versus placebo in second-line treatment, but results in enriched populations were not explored or documented in this trial so far.
Targeting c-MET
In addition, therapies targeting c-MET (mutated in 3% of the HCC, ►Table 2) are also under evaluation in HCC. Activation of MET signaling, through other mechanisms, in advanced HCC is estimated to be of 50%. 
Targeting Chromosomal Alterations
To date, none of the above-described agents and none of the phase 3 clinical trials have exceeded the benefits of sorafenib, neither in first-line nor in second-line treatment. 80 Further efforts to discover new therapeutic targets through integrated genomic approaches are expected to improve this. Promising results from genomic studies assessing chromosomal alterations seem to be one of the tools to identify novel HCC target genes. 96 Following the discovery of focal amplifications of VEGFA, a recent study described the beneficial effect of sorafenib treatment in patients with HCC bearing VEGFA gains.
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Additional chromosomal alterations have been recurrently identified in HCC (►Table 2). These include (1) the 8q gain that contains the c-myc proto-oncogene and for which quarfloxin, a VEGF TKI reducing c-myc mRNA levels, would be one of the candidate strategies to be tested 97 ; (2) 
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The second type of targeted therapies takes into consideration miRNA data. Recently, miRNAs have been identified as important regulators of gene expression with association to HCC, 102 and their value in clinical management, either as prognostic or diagnostic markers, has been demonstrated in several studies. 103 There is now accumulated evidence showing that molecular therapies based directed to miRNAs are a worthwhile alternative for cancer treatment.
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Resistance to Targeted Therapies
As is the case for other systemic cancer therapies, molecular targeted therapies are liable to generate acquired drug resistances. In addition to the alterations targeted by the drug, tumor cells have additional alterations that may trigger drugresistance mechanisms after the initial drug response. 78 This has been shown for crizotinib designed to inhibit the fusion protein EML4-ALK in nonsmall-cell lung cancer, 104 or for vemurafenib directed to B-Raf in melanoma. 105 Approaches to overcome this would be (1) merging strategies based on combining drugs specifically targeting drivers and broad spectrum drugs such as sorafenib, with strategies based on the molecular classification of the patients; and/or (2) generating second-generation drugs circumventing acquisition of resistance mechanisms. Moreover, targeting the microenvironment might be also fruitful in this sense. The gold standard for future treatment approaches in HCC is expected to be based on combined molecular-targeted therapies aimed at blocking HCC key molecular pathways differently altered according with the molecular classification of each patient. To make this a clinical reality, several issues remain to be elucidated in the near future: (1) Identification of the subset of patients that tumors are driven by a molecular aberration, and (2) elucidate the impact of tumor heterogeneity in the management of the disease. The complexity of etiologies and landscape of mutations make this an important issue. It is unknown whether different tumors from the same patient share the main drivers or different drivers. This concept will have implications in obtaining biopsies that represent a readout for the landscape of mutations. It is expected also that in the near future liquid biopsy might be a potential tool for capturing molecular heterogeneity.
